BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

...Drugs (LPAD). The aminoglycoside antibiotic came to Insmed via the company’s $84 million acquisition of Transave Inc....
...rinfibate and stopped selling the IGF-1 receptor agonist to new patients (see “Insmed combines with Transave”...
BioCentury | Aug 11, 2014
Clinical News

Arikace amikacin regulatory update

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....
BioCentury | Jun 23, 2014
Clinical News

Amikacin regulatory update

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....
BioCentury | Mar 31, 2014
Clinical News

Arikayce amikacin: Phase II data

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....
BioCentury | Mar 27, 2014
Clinical News

Insmed falls on Arikayce miss for non-TB lung infection

...cystic fibrosis (CF) patients. Insmed gained the inhaled liposomal amikacin through its 2010 acquisition of Transave Inc....
BioCentury | Mar 3, 2014
Clinical News

Arikace amikacin: Extension study data

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Oct 21, 2013
Clinical News

Arikace amikacin: Completed Phase II enrollment

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Jul 16, 2013
Top Story

Insmed proposes $60M follow-on

...of the inhaled liposomal amikacin last month. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Jul 15, 2013
Clinical News

Arikace: Phase III data

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Jul 2, 2013
Clinical News

Insmed falls on Phase III data for lung infection compound

...NTM) lung infection. Insmed gained Arikace, an inhaled liposomal amikacin, through its 2010 acquisition of Transave Inc. BC...
Items per page:
1 - 10 of 42
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

...Drugs (LPAD). The aminoglycoside antibiotic came to Insmed via the company’s $84 million acquisition of Transave Inc....
...rinfibate and stopped selling the IGF-1 receptor agonist to new patients (see “Insmed combines with Transave”...
BioCentury | Aug 11, 2014
Clinical News

Arikace amikacin regulatory update

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....
BioCentury | Jun 23, 2014
Clinical News

Amikacin regulatory update

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....
BioCentury | Mar 31, 2014
Clinical News

Arikayce amikacin: Phase II data

...the EU to treat NTM lung infection. Insmed gained Arikayce through its 2010 acquisition of Transave Inc....
BioCentury | Mar 27, 2014
Clinical News

Insmed falls on Arikayce miss for non-TB lung infection

...cystic fibrosis (CF) patients. Insmed gained the inhaled liposomal amikacin through its 2010 acquisition of Transave Inc....
BioCentury | Mar 3, 2014
Clinical News

Arikace amikacin: Extension study data

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Oct 21, 2013
Clinical News

Arikace amikacin: Completed Phase II enrollment

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Jul 16, 2013
Top Story

Insmed proposes $60M follow-on

...of the inhaled liposomal amikacin last month. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Jul 15, 2013
Clinical News

Arikace: Phase III data

...the U.S. to treat NTM lung infection. Insmed gained Arikace through its 2010 acquisition of Transave Inc....
BioCentury | Jul 2, 2013
Clinical News

Insmed falls on Phase III data for lung infection compound

...NTM) lung infection. Insmed gained Arikace, an inhaled liposomal amikacin, through its 2010 acquisition of Transave Inc. BC...
Items per page:
1 - 10 of 42